Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: a nested case-control study in nonsmoking postmenopausal women from the EPIC cohort

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Bueno de Mesquita H. B. as ) > (2016) > Acrylamide and glyc...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04884naa a2200829 4500
001		oai:DiVA.org:umu-118524
003		SwePub
008		160322s2016 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:prod.swepub.kib.ki.se:132859030
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1185242 URI
024	7	a https://doi.org/10.1002/ijc.298532 DOI
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:1328590302 URI
040		a (SwePub)umud (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Obón-Santacana, Mireia4 aut
245	1 0	a Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk :b a nested case-control study in nonsmoking postmenopausal women from the EPIC cohort
264		c 2015-10-01
264	1	b Wiley,c 2016
338		a print2 rdacarrier
520		a Acrylamide, classified in 1994 by IARC as "probably carcinogenic to humans," was discovered in 2002 in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The purpose of this nested case-control study, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum (HbAA+HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC was evaluated using unconditional multivariable logistic regression models, and included 383 EC cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1 : 0.84, 95%CI: 0.49-1.48; HRHbGA;Q5vsQ1 : 0.94, 95%CI: 0.54-1.63) or type-I EC risk. Additionally, none of the subgroups investigated (BMI < 25 vs. ≥25 kg m(-2) , alcohol drinkers vs. never drinkers, oral contraceptive users vs. non-users) demonstrated effect measure modification. Hemoglobin adducts of acrylamide or glycidamide were not associated with EC or type-I EC risk in 768 nonsmoking postmenopausal women from the EPIC cohort.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653		a hemoglobin adduct
653		a acrylamide
653		a glycidamide
653		a endometrial cancer
653		a EPIC
700	1	a Freisling, Heinz4 aut
700	1	a Peeters, Petra H4 aut
700	1	a Lujan-Barroso, Leila4 aut
700	1	a Ferrari, Pietro4 aut
700	1	a Boutron-Ruault, Marie-Christine4 aut
700	1	a Mesrine, Sylvie4 aut
700	1	a Baglietto, Laura4 aut
700	1	a Turzanski-Fortner, Renee4 aut
700	1	a Katzke, Verena A4 aut
700	1	a Boeing, Heiner4 aut
700	1	a Quirós, J Ramón4 aut
700	1	a Molina-Portillo, Elena4 aut
700	1	a Larrañaga, Nerea4 aut
700	1	a Chirlaque, María-Dolores4 aut
700	1	a Barricarte, Aurelio4 aut
700	1	a Khaw, Kay-Tee4 aut
700	1	a Wareham, Nick4 aut
700	1	a Travis, Ruth C4 aut
700	1	a Merritt, Melissa A4 aut
700	1	a Gunter, Marc J4 aut
700	1	a Trichopoulou, Antonia4 aut
700	1	a Lagiou, Pagona4 aut
700	1	a Naska, Androniki4 aut
700	1	a Palli, Domenico4 aut
700	1	a Sieri, Sabina4 aut
700	1	a Tumino, Rosario4 aut
700	1	a Fiano, Valentina4 aut
700	1	a Galassom, Rocco4 aut
700	1	a Bueno-de-Mesquita, H B As4 aut
700	1	a Onland-Moret, N Charlotte4 aut
700	1	a Idahl, Annikau Umeå universitet,Obstetrik och gynekologi,Näringsforskning4 aut0 (Swepub:umu)anid0002
700	1	a Lundin, Evau Umeå universitet,Patologi4 aut0 (Swepub:umu)evlu0001
700	1	a Weiderpass, Elisabeteu Karolinska Institutet4 aut
700	1	a Vesper, Hubert4 aut
700	1	a Riboli, Elio4 aut
700	1	a Duell, Eric J4 aut
710	2	a Umeå universitetb Obstetrik och gynekologi4 org
773	0	t International Journal of Cancerd : Wileyg 138:5, s. 1129-1138q 138:5<1129-1138x 0020-7136x 1097-0215
856	4	u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.29853
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-118524
856	4 8	u https://doi.org/10.1002/ijc.29853
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:132859030

Hitta via bibliotek

International Journal of Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: International Jo ...

Av lärosätet: Umeå universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se